Fluothane

Quick links to important sections

Fluothane

Method of action: Anesthesia, Anesthetic

Treatment option: Anesthesia, General Anesthesia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluothane

This section provides a foundational overview of the drug Fluothane, defining its composition, classification, and general purpose as a potent anesthetic agent, highlighting its unique delivery method and historical significance.

Property Description
Active ingredient Halothane
Form Volatile liquid (for inhalation)
Pharmacological class General Anesthetic
Common use Induction and maintenance of anesthesia
Origin Synthetic (Halogenated Alkane)

What Type of Medicine is Fluothane?

Fluothane is the trade name for the active compound Halothane (INN), a highly potent, single-ingredient substance classified as a general anesthetic. Chemically, it belongs to the group of halogenated alkanes. Its essential purpose is to induce and maintain a controlled, reversible state of unconsciousness necessary for surgical procedures. The chemical classification of Halothane as a volatile inhalation anesthetic has been foundational in the history of anesthesia. This classification underlines the drug's role as a major agent used to safely abolish a patient's consciousness and pain perception.

Composition and Unique Volatile Form

Halothane is supplied as a clear, colorless volatile liquid, a unique formulation that easily converts into a breathable vapor when administered via a specialized, calibrated vaporizer. This preparation is entirely synthetic and non-flammable, and does not contain other active compounds. Halothane is categorized as a liquid for vaporization, strictly for the route of inhalation. This delivery method allows medical teams immediate and precise control over the anesthetic's concentration within the patient's system to manage the depth of anesthesia during complex surgeries.

General Purpose: Inducing a State of Anesthesia

The general purpose of Fluothane is the induction and sustained maintenance of general anesthesia for patients undergoing surgery. This action is achieved through a powerful, reversible effect known as Central Nervous System (CNS) depression. Halothane provides necessary anesthetic care in diverse clinical settings, including pediatric use. This action safely suspends the brain's ability to process pain, form memories, and initiate movement, creating the controlled state required for surgical success.

Regulatory References

  1. Halothane on WHO Model List of Essential Medicines

What side effects are possible with Fluothane?

Possible Side Effects and Safety Information

The safety profile of Fluothane (halothane) is defined by officially documented, dose-dependent effects primarily on the cardiovascular and respiratory systems, alongside specific rare but serious adverse reactions listed in regulatory documents.


Cardiovascular and Systemic Effects

Side effects affecting the cardiovascular system are frequently observed and classified as common or very common. These include hypotension (decreased blood pressure), bradycardia (slowed heart rate), and various cardiac arrhythmias, which may be more frequent during the induction phase of anesthesia. Halothane also causes a dose-dependent respiratory depression.

Common post-operative symptoms, classified in official documents, include nausea, vomiting, shivering, and headache. The agent is also documented to potentially increase cerebrospinal fluid pressure.


Serious Adverse Reactions and Safety Constraints

Official labeling emphasizes the risk of two rare but serious conditions. Halothane is a potent trigger for Malignant Hyperthermia (MH) crisis, a life-threatening, inherited hypermetabolic state. Additionally, severe hepatic necrosis (often termed Halothane hepatitis) is a rare but potentially fatal risk. Regulatory documents note that the risk of severe liver injury is substantially increased by repeated exposure.

Population-specific safety constraints exist regarding obstetrics, as the agent causes relaxation of the uterine smooth muscle, which is associated with an increased risk of postpartum hemorrhage. Caution is also required in co-administration with catecholamines, as Halothane sensitizes the heart and may induce severe ventricular arrhythmias.

Overdose and Emergency Response

Fluothane overdose is officially defined by severe, acute cardiovascular and respiratory depression resulting from high inspired concentrations of the anesthetic. Documented clinical manifestations of overexposure include profound hypotension (severely low blood pressure) and bradycardia (abnormally slow heart rate). The regulatory profile specifies that overdosage carries a serious risk of life-threatening outcomes such as cardiac arrest and respiratory arrest. These outcomes necessitate immediate, urgent medical intervention as defined by official labeling.

In the event of suspected overdose, regulators mandate that Fluothane administration must cease immediately. Following this, the official management is procedural: the patient must be ventilated mechanically to ensure acceptable blood gases are restored. Since regulatory documents confirm no specific antidote is known for acute Halothane overexposure, the required treatment for overdosage is universally defined as symptomatic and supportive treatment. Official guidance requires the patient to be closely observed with continuous monitoring of respiration, pulse rate, and blood pressure during the emergency period. Immediate medical help must be sought for all cases of accidental severe acute exposure.

Therapeutic Uses of Fluothane

What Fluothane Treats: Therapeutic Applications and Supportive Actions

Fluothane (halothane) is a volatile agent primarily applied across domains where short-term symptom management is appropriate, such as in settings marked by heightened systemic burden. Its primary application is for the induction and maintenance of general anesthesia.

The medication is applied in addressing symptom clusters that may become intense or disruptive during acute medical procedures, including symptoms related to heightened physiological activity (pain, movement, and awareness) and symptoms that create noticeable physiological strain in the airways. This supportive action is relevant when temporary symptomatic assistance is needed to ease the overall symptom burden.

“It is relevant in clinical settings that involve acute or unstable symptom patterns, where temporary assistance in symptom stabilization is helpful.”

Quick Fact: Support for Acute Symptom Manifestations

The primary therapeutic applications are focused on conditions characterized by periods of heightened symptoms, specifically during general anesthesia for medical and surgical procedures, and in situations requiring temporary management of acute airway constriction (bronchospasm). The use of this agent is associated with assisting with maintaining functional stability and supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH LiverTox Halothane Overview

Eligibility and Restrictions for Use

Fluothane, the brand name for halothane, is a potent inhalational agent used for the induction and maintenance of general anesthesia in both adults and children. Its non-irritant properties made it a historical choice for inhalation induction, particularly in pediatric patients.


Contraindications and Use Restrictions

Due to its potential for serious side effects, Fluothane is contraindicated or restricted in certain patient populations. It should not be used in patients with a known history of:

  • Unexplained jaundice or fever following prior exposure to halothane.
  • A personal or family history of malignant hyperthermia, a rare but life-threatening reaction to general anesthetics.
Patient Group Restriction / Caution
Prior Halothane Exposure Generally avoided within three months of previous use due to increased risk of liver injury (halothane hepatitis).
Liver Dysfunction Used with extreme caution, as it is associated with hepatotoxicity (liver damage).
Obstetrics Generally not recommended for obstetrical anesthesia, as it reduces uterine tone and may increase the risk of postpartum hemorrhage.
Intracranial Pressure Caution is needed in patients with markedly raised intracranial pressure, as the agent can increase cerebrospinal fluid pressure.

Fluothane has been largely replaced in developed countries by newer agents like sevoflurane due to its side effect profile, but it remains on the World Health Organization's List of Essential Medicines.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fluothane (halothane) has officially documented interactions with several classes of medicinal products, primarily involving effects on the cardiovascular and neuromuscular systems. These interactions may necessitate caution or adjustment in co-administered agents.

Documented Interacting Categories

  • Sympathomimetics: Co-administration with agents such as adrenaline (epinephrine) requires caution, as Fluothane sensitizes the myocardial conduction tissue, increasing the risk of cardiac arrhythmias. This applies also to other sympathomimetics, as well as aminophylline, theophylline, and tricyclic antidepressants, which may similarly precipitate arrhythmias.
  • Neuromuscular Blocking Agents: The drug potentiates the action of non-depolarising muscle relaxants, such as tubocurarine, augmenting the degree of muscle relaxation achieved. This effect is also noted with aminoglycoside antibiotics, which can cause augmented muscle relaxant effects.
  • Cardiovascular Agents: Fluothane potentiates the effects of antihypertensive agents, potentially leading to greater reductions in blood pressure. Use with amiodarone is noted to increase the risk of atropine-resistant bradycardia and hypotension.

The overall interaction structure is defined by an augmented risk of additive cardiovascular effects (arrhythmias and hypotension) and enhanced neuromuscular blockade when specific categories of agents are co-administered.

Mechanism of Action

How Fluothane Works: Mechanism of Action


Modulating Central Nervous System (CNS) Signaling

This mechanism involves enhancing the activity of the brain’s primary inhibitory receptors (like GABA A and Glycine) while simultaneously blocking the effect of excitatory receptors (like NMDA). This widespread shift in the brain's signaling balance leads to a reversible suppression of neuronal activity, resulting in a state characterized by widespread central nervous system depression, which includes suppressed awareness and altered memory processing.


Direct Depression of Cardiac and Respiratory Systems

Fluothane also acts directly on non-neuronal cells by inhibiting voltage-gated ion channels, such as L-type Calcium channels in the heart muscle. This action suppresses the contractility of the myocardium (heart muscle) and reduces the responsiveness of the brainstem's respiratory control centers. These effects result in decreased contractility and responsiveness in the heart and respiratory centers, causing a reduction in blood pressure and ventilation.


Suppression of Motor Pathways

This domain involves the drug's effect on the spinal cord, where it acts to block the conduction of electrical signals necessary for muscle activation. By interrupting the motor commands and reflex arcs, this mechanism contributes to the suppression of involuntary movement and reflex activity, resulting in a state of immobility and muscle relaxation.

Dosage and Administration Information

Administration Guidelines

Fluothane (Halothane) is a volatile liquid intended for administration by inhalation. As a general anesthetic agent, its use is reserved for administration by individuals who are trained in the administration of general anesthesia.

Procedural and Dosing Requirements

Delivery involves the use of a specialized calibrated vaporizer designed to provide a known concentration of halothane vapor, allowing for control over the dosage. The liquid is vaporized and administered with either oxygen or a mixture of oxygen and nitrous oxide. The concentrations used vary depending on the stage of the procedure and the patient's age.

Administration Stage Concentration Range (Volume/Volume)
Induction (Adults) 2% to 4% v/v; may begin at 0.5% v/v and increase gradually
Maintenance (Adults) 0.5% to 2% v/v
Induction (Pediatric) 1.5% to 2% v/v

For elderly patients, lower maintenance concentrations, such as 0.5% v/v, are often utilized. The dosage is individualized based on the patient’s response. Since this is a single-administration product for a controlled surgical procedure, there are no instructions regarding missed doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fluothane

Evidence for Induction and Maintenance of General Anesthesia

Research into Fluothane (Halothane) includes a substantial volume of Randomized Controlled Trials (RCTs) and comparative studies involving adult surgical patients. These studies focused on outcomes related to systemic or functional imbalance required for surgery. Researchers examined key metrics such as the time needed for patients to achieve anesthesia (loss of consciousness) and the time required for patients to regain full consciousness and emerge from the anesthetic state.

Findings describe patterns observed in these studies regarding the speed of induction and recovery. Data show patterns related to physiological outcomes, such as heart rate and blood pressure, that were monitored during the procedure. The evidence contributes to the broader evidence landscape where researchers have historically compared this agent against newer inhalation agents. Short-term trials also examined the quality of anesthesia, including the conditions for surgical procedures.

Evidence in Pediatric Patients

A significant body of research has explored the administration of Fluothane for inhalation induction, particularly in pediatric patients, including infants and neonates. These studies often used comparative designs to evaluate the patient's experience during the induction phase, which is a key period associated with acute or disruptive episodes. Research examined outcomes related to physical discomfort and outcomes capturing phases of heightened symptom activity, such as the patient's acceptance of the mask and the presence of coughing or salivation during the process.

Studies monitored the physiological response of children, particularly focusing on how heart rate and blood pressure evolved in the observed populations during the start of anesthesia. Post-procedure research also focused on functional measures, such as post-operative maladaptive behavior or emergence agitation, for defined time intervals. The evidence base describes patterns related to the agent's administration in the context of common pediatric anesthetic techniques.

What is Still Uncertain About Fluothane's Research Base

The research base has been characterized by several limitations. Specifically, results apply only to the populations studied in the historical context of its development, and comparative evidence is often lacking against the latest generation of inhaled anesthetics. The follow-up durations were generally limited, meaning there is limited information for long-term outcomes, especially regarding functional or cognitive measures assessed months after administration. Furthermore, data for certain specialized groups, such as very frail or severely comorbid patients, remain insufficient in the core clinical trial record.

Key Studies & References

  1. Halothane - LiverTox - National Library of Medicine
  2. Halothane (Fluothane) Drug Label Information (FDA historical source)

Frequently Asked Questions (FAQ)

Common questions about Fluothane (FAQ)

Q: Are there any common interactions between Fluothane and regular pain medication?

Official drug interaction lists describe potential interactions with various medications, including common over-the-counter pain relievers like acetaminophen and aspirin, and the pain reliever morphine. Regulatory documents state that it is important that the medical team receives full information about all medications and supplements being taken before the drug is administered.


Q: Is there a maximum age limit for using Fluothane?

Regulatory guidelines define specific administration concentrations for different age groups, including lower amounts for elderly patients. Official documents, however, do not specify a definitive maximum age limit beyond which the drug cannot be used.


Q: Can Fluothane be used if a person has a history of respiratory problems?

Official product information indicates that Fluothane progressively slows down breathing (respiratory depression) in a way that depends on the administered amount. Although it may have a dilating effect on the airways, its use is typically managed with careful monitoring, especially in patients where pre-existing respiratory issues may be a concern.


Q: Does Fluothane have any lasting effects on memory or cognition?

The state of general anesthesia is described in official documents as involving temporary, altered memory processing during the procedure. However, regulatory sources note a historical limitation in the research base regarding long-term functional or cognitive outcomes assessed many months after the drug's administration.


Q: Are there official statements about Fluothane's use during pregnancy or breastfeeding?

Regulatory information describes a caution against use for obstetrical anesthesia because it relaxes the uterine smooth muscle, which may increase the risk of postpartum hemorrhage (excessive bleeding after delivery). Regulatory information also describes caution regarding breastfeeding following administration.


Q: Is the main purpose of Fluothane just to cause sleep, or does it also block pain?

The primary purpose of the drug is the induction and maintenance of general anesthesia, a controlled state defined by the suspension of consciousness, memory, and pain perception. While it is known for its sleep-inducing effects, regulatory sources do not formally classify Fluothane as an analgesic (a pain-blocking drug) in isolation.


Q: What does 'contraindication' mean in relation to Fluothane?

A contraindication defines a condition under which a drug is not administered because the potential risks may outweigh the benefits. According to official labeling, key contraindications for Fluothane include a personal or family history of malignant hyperthermia or a history of unexplained fever or jaundice after previous exposure to the anesthetic.


Q: Can people with a history of serious illness still be eligible for Fluothane?

Official documents state that the dosage is highly individualized and its use involves extreme caution for patients with underlying conditions affecting the liver, heart, or brain function. Regulatory reviews also point out that the core clinical research base has insufficient data for very frail or severely comorbid patients.


Q: What happens to Fluothane once it's inside the body?

Once Fluothane is inhaled, official pharmacokinetic data indicates that about 15% to 20% of the drug is processed (metabolized) by enzymes in the liver. The resulting breakdown products, such as trifluoroacetic acid, are then gradually eliminated from the body, primarily through the urine.


Q: Is Fluothane used for procedures other than surgery?

According to official regulatory labeling, Fluothane is specifically indicated for the induction and maintenance of general anesthesia necessary for surgical and related medical procedures. While some historical investigation into specialized non-surgical uses has occurred, the drug's official purpose remains centered on providing anesthesia.


Q: Are there certain dietary supplements or herbal remedies that interact with Fluothane?

Regulatory interaction lists mention that certain herbal remedies and dietary supplements, such as ginkgo biloba, may have moderate to major interactions with the anesthetic. Official information highlights the importance of full disclosure of all supplements and herbal remedies to the anesthetic team before administration.


Q: How is the effect of Fluothane monitored during a procedure?

During the procedure, the amount of the drug delivered is continuously regulated using a specialized, calibrated vaporizer. Beyond controlling the drug dose, the clinical practice involves constant monitoring of the patient's physiological state for key effects, including changes in blood pressure (hypotension), heart rate, and any irregular heart rhythms.


Q: Can a patient with certain allergies still use Fluothane?

Official sources state that severe immune-mediated reactions, including hypersensitivity and anaphylaxis, have been reported in the context of anesthesia involving Fluothane and other necessary adjunct medications. Furthermore, the drug’s processing in the body has been linked to immune-related liver injury. It is necessary for patients to disclose all known drug allergies to the anesthetic team.


Q: Are there official warnings about combining Fluothane with alcohol, even before the procedure?

Official safety summaries contain warnings that long-term, chronic consumption of alcohol may increase the risk of liver damage associated with Fluothane. This is because both alcohol and the anesthetic are processed in the liver. Official guidance highlights the necessity of providing information to the medical team about alcohol use history before the anesthetic is administered.


Q: What is the difference between general and regional anesthesia when Fluothane is used?

Fluothane is classified as a general anesthetic, which works by causing widespread central nervous system depression, leading to a loss of consciousness and sensation across the entire body. This is distinct from regional anesthesia, which is designed to block feeling only in a specific, limited area without causing a complete loss of consciousness.


Q: Is it possible to have an allergic reaction to Fluothane?

Regulatory documents confirm that it is possible to experience severe immune-mediated reactions, including hypersensitivity and anaphylaxis, although these events are rare and often involve other medications used during the anesthetic process. The drug’s processing in the body has also been noted as a potential trigger for immune-mediated liver injury.


Q: What does the research say about Fluothane's use in dental procedures?

Official regulatory guidance describes limitations on the use of Fluothane for pediatric dental procedures, restricting it to hospital settings only. This is due to noted safety risks, including the drug's effect of making the heart more sensitive to certain substances (catecholamines), which can increase the risk of serious irregular heart rhythms (cardiac arrhythmias).


Q: Does Fluothane interact with common blood thinners?

Official drug interaction lists mention potential interactions with specific blood-thinning medications, such as heparin. Regulatory guidance stresses the importance of informing the anesthetic team about all anticoagulant or blood-thinning medications being taken by the patient prior to the procedure.


Q: What is the official description of Fluothane's use in patients with a history of seizures?

Official product information indicates that Fluothane has been associated with adverse central nervous system (CNS) effects, including reports of headaches, delirium, and seizures. Due to these potential effects, the decision regarding its use is made by the physician on a case-by-case basis.


Q: What are the official guidelines regarding the use of Fluothane in obese patients?

Regulatory texts stress that the anesthetic dosage must always be carefully individualized based on the patient's unique response. Due to the high fat-solubility of the drug, official literature notes that Fluothane may have altered distribution and elimination in patients with morbid obesity, which necessitates special consideration and careful management in the clinical setting.

How should Fluothane be stored and disposed of?

How to Store and Dispose of Fluothane?

The storage and disposal of Fluothane (Halothane) are governed by its status as a volatile, light-sensitive liquid, requiring strict adherence to regulatory standards to maintain stability.

Official Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (or 68 F to 77 F).
Protection Mandatory protection from light; must be stored in the original carton and in tightly closed, amber-colored bottles.
Stability Rule The stabilizer, thymol, can leave residue; discolored product must be discarded. Vapourizers must be emptied at the end of each operating day.

Official Disposal Instructions

Any unused or expired product must be disposed of in accordance with local environmental and regulatory requirements. In the event of a spill, the liquid must be collected in sealable containers and absorbed with an inert absorbent material before proper disposal, as defined by hazardous waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluothane found in:

A-Z Index: